INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that uniQure and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 13, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired uniQure securities during the Class Period [2]. Group 2: Company Developments - On November 3, 2025, uniQure announced feedback from the U.S. FDA regarding its investigational gene therapy AMT-130 for Huntington's disease, indicating a shift in the FDA's stance on the adequacy of data from Phase I/II studies for a Biologics License Application (BLA) submission [4]. - Following this announcement, uniQure's stock price dropped by $33.40 per share, or 49.34%, closing at $34.29 per share on the same day [4].